Immix Biopharma
IMMX
7 hedge funds and large institutions have $475K invested in Immix Biopharma in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.
35% more capital invested
Capital invested by funds: $352K → $475K (+$123K)
0.61% less ownership
Funds ownership: 1.93% → 1.32% (-0.61%)
13% less funds holding
Funds holding: 8 → 7 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$143K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.4K |
| 3 |
State Street
Boston,
Massachusetts
|
+$75.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.47K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$86 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$151K |
| 2 |
VF
Virtu Financial
New York
|
-$57K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$52K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$31K |
| 5 |
BlackRock
New York
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $190K | +$143K | +73,333 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $132K | +$99.4K | +50,905 | New |
|
|
3
State Street
Boston,
Massachusetts
| $100K | +$75.3K | +38,560 | New |
|
|
ICG
4
InterOcean Capital Group
Nashville,
Tennessee
| $41K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $11K | +$8.47K | +4,337 | New |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
7
Renaissance Technologies
New York
| – | -$151K | -62,600 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$57K | -23,515 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$52K | -21,713 | Closed |
|
|
XT
10
XTX Topco
George Town,
Cayman Islands
| – | -$31K | -12,992 | Closed |
|
|
11
BlackRock
New York
| – | -$22K | -9,415 | Closed |
|
|
12
Wells Fargo
San Francisco,
California
| – | +$86 | +44 | +169% |
|
IMMX Hedge Fund Activity: Q2 2022 in Review
7 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q2 2022, worth a combined $475K — up 35% from $352K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMMX and 4 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $143K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $151K sold.
- 7 institutional investors held Immix Biopharma (IMMX) as of Q2 2022, down from 8 in Q1 2022.
- Funds reported $475K of Immix Biopharma stock for Q2 2022, up 35% quarter-over-quarter.
- 4 funds opened new Immix Biopharma positions in Q2 2022 and 5 closed out, a net change of -1 holder.
- The largest Immix Biopharma buyer in Q2 2022 was Geode Capital Management, an estimated $143K added.
- The largest Immix Biopharma seller in Q2 2022 was Renaissance Technologies, an estimated $151K sold.
Based on aggregated 13F filings for Q2 2022.